The clonal structure and dynamics of the human T cell response to an organic chemical hapten

  1. Tahel Ronel
  2. Matthew Harries
  3. Kate Wicks
  4. Theres Oakes
  5. Helen Singleton
  6. Rebecca Dearman
  7. Gavin Maxwell
  8. Benny Chain  Is a corresponding author
  1. University College London, United Kingdom
  2. University of Manchester, United Kingdom
  3. Unilever, United Kingdom

Abstract

Diphenylcyclopropenone (DPC) is an organic chemical hapten which induces allergic contact dermatitis, and is used in treatment of warts, melanoma and alopecia areata. This therapeutic setting therefore provided an opportunity to study T cell receptor (TCR) repertoire changes in response to hapten sensitization in humans. Repeated exposure to DPC induced highly dynamic transient expansions of a polyclonal diverse T cell population. The number of TCRs expanded early after sensitization varies between individuals, and predicts the magnitude of the allergic reaction. The expanded TCRs show preferential TCR V and J gene usage, and consist of clusters of TCRs with similar sequences, two characteristic features of antigen-driven responses. The expanded TCRs share subtle sequence motifs that can be captured using a Dynamic Bayesian Network. These observations suggest the response to DPC is mediated by a polyclonal population of T cells recognizing a small number of dominant antigens.

Data availability

All DNA sequences have been submitted to the Short Read Archive under identifier SUB6567504 .

The following data sets were generated

Article and author information

Author details

  1. Tahel Ronel

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9513-9181
  2. Matthew Harries

    Faculty of biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  3. Kate Wicks

    Faculty of biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  4. Theres Oakes

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  5. Helen Singleton

    Faculty of biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  6. Rebecca Dearman

    Faculty of biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  7. Gavin Maxwell

    Safety and Environmental Assurance Centre, Unilever, Bedford, United Kingdom
    Competing interests
    Gavin Maxwell, GM is an employee of Unilever PLC. Apart from GM's contribution (see author contributions) the funder was not involved in the study design, collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication..
  8. Benny Chain

    Infection and Immunity, University College London, London, United Kingdom
    For correspondence
    b.chain@ucl.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7417-3970

Funding

Unilever

  • Benny Chain

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Armita Nourmohammad, University of Washington, United States

Ethics

Human subjects: The protocol was approved by the University College London Hospital Ethics Committee 06/Q0502/92. A total of 34 patients were recruited to this study (NRES Ethics Committee East of England - Cambridgeshire and Hertfordshire [14/EE/1067]). Participants were recruited from patients who had been diagnosed with alopecia, were aged between 18 and 70, identified as suitable for DPC treatment by a consultant dermatologist, and were now attending their first visit to the Alopecia Clinic at Salford Royal Hospital for DPC therapy. This study ran alongside patients' prescribed DPC treatment (weekly doses of DPC to the scalp to induce inflammation and hair regrowth). All participants gave their informed consent to participate, and were free to withdraw from the study at any time and for any reason without affecting their treatment. Patients were excluded from the study if they were pregnant.

Version history

  1. Received: December 27, 2019
  2. Accepted: January 12, 2021
  3. Accepted Manuscript published: January 12, 2021 (version 1)
  4. Version of Record published: February 12, 2021 (version 2)

Copyright

© 2021, Ronel et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,149
    views
  • 131
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tahel Ronel
  2. Matthew Harries
  3. Kate Wicks
  4. Theres Oakes
  5. Helen Singleton
  6. Rebecca Dearman
  7. Gavin Maxwell
  8. Benny Chain
(2021)
The clonal structure and dynamics of the human T cell response to an organic chemical hapten
eLife 10:e54747.
https://doi.org/10.7554/eLife.54747

Share this article

https://doi.org/10.7554/eLife.54747

Further reading

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Jean-David Larouche, Céline M Laumont ... Claude Perreault
    Research Article

    Transposable elements (TEs) are repetitive sequences representing ~45% of the human and mouse genomes and are highly expressed by medullary thymic epithelial cells (mTECs). In this study, we investigated the role of TEs on T-cell development in the thymus. We performed multiomic analyses of TEs in human and mouse thymic cells to elucidate their role in T-cell development. We report that TE expression in the human thymus is high and shows extensive age- and cell lineage-related variations. TE expression correlates with multiple transcription factors in all cell types of the human thymus. Two cell types express particularly broad TE repertoires: mTECs and plasmacytoid dendritic cells (pDCs). In mTECs, transcriptomic data suggest that TEs interact with transcription factors essential for mTEC development and function (e.g., PAX1 and REL), and immunopeptidomic data showed that TEs generate MHC-I-associated peptides implicated in thymocyte education. Notably, AIRE, FEZF2, and CHD4 regulate small yet non-redundant sets of TEs in murine mTECs. Human thymic pDCs homogenously express large numbers of TEs that likely form dsRNA, which can activate innate immune receptors, potentially explaining why thymic pDCs constitutively secrete IFN ɑ/β. This study highlights the diversity of interactions between TEs and the adaptive immune system. TEs are genetic parasites, and the two thymic cell types most affected by TEs (mTEcs and pDCs) are essential to establishing central T-cell tolerance. Therefore, we propose that orchestrating TE expression in thymic cells is critical to prevent autoimmunity in vertebrates.

    1. Immunology and Inflammation
    Toyoshi Yanagihara, Kentaro Hata ... Isamu Okamoto
    Research Article

    Anticancer treatments can result in various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity in the lung. One of the major opportunistic infections is Pneumocystis jirovecii pneumonia (PCP), which can cause severe respiratory complications and high mortality rates. Cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs). Nonetheless, the differentiation of these diseases can be difficult, and the pathogenic mechanisms of such diseases are not yet fully understood. To better comprehend the immunophenotypes, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with PCP, cytotoxic drug-induced ILD (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers. In PCP, we observed an expansion of the CD16+ T cell population, with the highest CD16+ T proportion in a fatal case. In ICI-ILD, we found an increase in CD57+ CD8+ T cells expressing immune checkpoints (TIGIT+ LAG3+ TIM-3+ PD-1+), FCRL5+ B cells, and CCR2+ CCR5+ CD14+ monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.